Overview

Study of Single IV Administration of P2G12

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

A randomised phase I trial of a monoclonal antibody which neutralises HIV-1 (P2G12) to be given as a single intravenous infusion to healthy human volunteers to assess the safety and reactogenicity

Phase:

Phase 1

Details

Lead Sponsor:

St George's, University of London

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins